Journal Title：American Journal Of Cardiovascular Drugs

Promoting rational therapy within the discipline of cardiology, the American Journal of Cardiovascular Drugs covers all aspects of the treatment of cardiovascular disorders, particularly the place in therapy of newer and established agents.

Via a program of reviews and original clinical research articles, the journal addresses major issues relating to treatment of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of cardiovascular disorders; and the practical management of specific clinical situations.

The American Journal of Cardiovascular Drugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager?, supported by a database of international experts. This database is shared with other Adis journals.

《美國(guó)心血管藥物雜志》旨在促進(jìn)心臟病學(xué)領(lǐng)域的合理治療，涵蓋了心血管疾病治療的各個(gè)方面，特別是新藥和成熟藥物在治療中的作用。

通過(guò)一系列評(píng)論和原創(chuàng)臨床研究文章，該雜志探討了與這些疾病治療相關(guān)的主要問(wèn)題，包括主要藥物類別的藥理學(xué)、療效和不良反應(yīng)；新開(kāi)發(fā)藥物和藥物類別的信息；心血管疾病病因?qū)W最新研究的治療意義；以及特定臨床情況的實(shí)際管理。

《美國(guó)心血管藥物雜志》提供了一系列額外的增強(qiáng)功能，旨在提高雜志內(nèi)容的可見(jiàn)性、讀者群和教育價(jià)值。每篇文章都附有要點(diǎn)摘要，為廣大讀者提供內(nèi)容的省時(shí)概述。文章可能附有通俗易懂的語(yǔ)言摘要，以幫助患者、護(hù)理人員和其他人了解重要的醫(yī)學(xué)進(jìn)展。該雜志還提供包括幻燈片集、視頻和動(dòng)畫(huà)等各種其他類型的增強(qiáng)功能的選項(xiàng)。所有增強(qiáng)功能都經(jīng)過(guò)同行評(píng)審，標(biāo)準(zhǔn)與文章本身一樣高。同行評(píng)審使用 Editorial Manager? 進(jìn)行，由國(guó)際專家數(shù)據(jù)庫(kù)支持。該數(shù)據(jù)庫(kù)與其他 Adis 期刊共享。

American Journal Of Cardiovascular Drugs創(chuàng)刊于2001年，由Springer International Publishing出版商出版，收稿方向涵蓋醫(yī)學(xué) - 心血管系統(tǒng)全領(lǐng)域，此期刊水平偏中等偏靠后，在所屬細(xì)分領(lǐng)域中專業(yè)影響力一般，過(guò)審相對(duì)較易，如果您文章質(zhì)量佳，選擇此期刊，發(fā)表機(jī)率較高。平均審稿速度 12周，或約稿 ，影響因子指數(shù)2.8，該期刊近期沒(méi)有被列入國(guó)際期刊預(yù)警名單，廣大學(xué)者值得一試。